Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights

Open access
Shi, Lei, Zhang, Ziying, Mei, Song, Wang, Zerui, Xu, Zhe, Yao, Weiqi, Liu, Limin, Yuan, Mengqi, Pan, Yuefei, Zhu, Kaidi, Liu, Kai, Meng, Fanglin, Sun, Jiao, Liu, Wenying, Xie, Xiaohui, Dong, Tengyun, Huang, Lei, Meng, Fanping, Fu, Jun-Liang, Li, Yuanyuan, Zhang, Chao, Fan, Xing, Shi, Ming, Zhang, Yu, Li, Yonggang, Xie, Wei-Fen, Zhang, Peng, Wang, Fu-Sheng · 2025 · Signal Transduction and Targeted Therapy

Abstract

Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal dosing strategies and dose-dependent therapeutic mechanisms in humans remain unclear, limiting its clinical application. We conducted sequential Phase Ia/Ib trials using a single-arm, dose-escalation design to evaluate the safety and tolerability of MSC therapy in DLC patients while also exploring its immunomodulatory effects and gathering preliminary therapeutic signals. In Phase Ia, four dose cohorts received a single dose of MSCs: 5.0 × 10⁷, 1.0 × 10⁸, 1.5 × 10⁸, and 2.0 × 10⁸ cells. Patients were followed up on Days 3, 7, 14, and 28. Multiomics analyses, including single-cell RNA sequencing and cytometry by time of flight, were conducted to perform exploratory mechanistic analyses investigating immune cell dynamics and dose-dependent responses. Building on these findings, Phase Ib included two dose cohorts, each of which received three doses of MSCs administered one week apart: 1.0 × 10⁸ and 2.0 × 10⁸ cells per dose. Patients were followed up on Days 7, 14, 21, and 28 to further evaluate the safety and feasibility of multiple-dose regimens. The trials were registered at ClinicalTrials.gov (NCT05227846 and NCT05984303). MSC therapy demonstrated good safety and tolerability in both Phase Ia and Phase Ib trials, with no severe adverse events, dose-limiting toxicities, or serious unexpected adverse reactions observed up to Day 28. Multi-omics analyses revealed that higher MSC doses elicited stronger immunomodulatory effects, particularly by modulating monocyte subsets. In particular, myxovirus resistance 1 positive (MX1 + ) monocytes, a key monocyte population, exhibited dose-dependent changes and were identified as a mediator of MSC-induced immunomodulation. These effects were sustained for up to seven days post-treatment but diminished by Day 14. Preliminary clinical signals included improvements in Child–Pugh scores, Model for End-Stage Liver Disease scores, liver function markers, and quality-of-life metrics, particularly in the higher-dose and multiple-dose groups. This study demonstrates the safety and tolerability of MSC therapy in patients with DLC and provides the first human-based evidence on the dose‒effect relationship and optimal administration regimens. The identification of MX1 + monocytes as a critical mediator highlights the potential of MSC therapy to modulate immune dysfunction in DLC. These findings offer valuable insights for optimizing MSC therapy and informing the design of future efficacy-focused clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-025-02318-4

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design. a Phase Ia; b Phase Ib. scRNA-seq (single-cell RNA sequencing) profiles transcriptomes across thousands of individual cells, whereas CyTOF (cytometry by time of flight) uses metal-tagged antibodies to simultaneously quantify >40 protein markers at single-cell resolution. Integrated analysis enables cross-validation between immune cell surface protein expression and transcriptional states
Fig. 1 Study design. a Phase Ia; b Phase Ib. scRNA-seq (single-cell RNA sequencing) profiles transcriptomes across thousands of individual cells, whereas CyTOF (cytometry by time of flight) uses metal-tagged antibodies to simultaneously quantify >40 protein markers at single-cell resolution. Integrated analysis enables cross-validation between immune cell surface protein expression and transcriptional statesCC BY · PubMed Central
Fig. 2 Changes in individual Child‒Pugh scores from baseline to Day 28. A child class A; B child class B; C child class C
Fig. 2 Changes in individual Child‒Pugh scores from baseline to Day 28. A child class A; B child class B; C child class CCC BY · PubMed Central
Fig. 3 The dynamic single-cell landscape of DLC patients under MSC treatment. a Schematic diagram of the multiomics analysis of cohorts in the clinical trial and the validation cohort. b Uniform manifold approximation and projection (UMAP) plots of the annotated cell lineages (left) and subpopulations (right) at a relatively high resolution. The cell clusters were annotated via canonical markers. c Boxplot showing the dynamics of the four major immune cell lineages. Lineage proportions were calculated as the percentage of total immune cells. d UMAP plot of the annotated monocyte subpopulations (left) and the expression of CD14 and FCGR3A (right). e Heatmap showing the scaled signature scores of the KEGG signaling pathways across monocyte subpopulations. The signature scores were calculated via the “AddModuleScore” function in Seurat. f Boxplot showing the dynamics of the five monocyte subpopulations. Cell proportions were calculated as the percentage of total monocytes. g Boxplot showing the fold change in cell proportions of c36_Mono_LGALS2 and c38_mono_MX1 at different MSC treatment time points compared with baseline across the three cohorts of DLC patients. h Boxplot showing the dynamics of the CCR+ cMono proportion in CyTOF. i Violin plot showing the signature score of the cytokine production process in c38_mono_MX1. Related genes were derived from the Gene Ontology database. j Heatmap of bulk RNA-seq data showing the expression of MX1+ monocyte-specific genes before and after coculture with MSCs. The Wilcoxon rank-sum test was used to test the difference in cell proportion between groups (p-values highlighted in red) and between posttreatment and baseline in each cohort (p-values highlighted in the corresponding cohort color). ***p < 0.001. **p < 0.01. *p < 0.05
Fig. 3 The dynamic single-cell landscape of DLC patients under MSC treatment. a Schematic diagram of the multiomics analysis of cohorts in the clinical trial and the validation cohort. b Uniform manifold approximation and projection (UMAP) plots of the annotated cell lineages (left) and subpopulations (right) at a relatively high resolution. The cell clusters were annotated via canonical markers. c Boxplot showing the dynamics of the four major immune cell lineages. Lineage proportions were calculated as the percentage of total immune cells. d UMAP plot of the annotated monocyte subpopulations (left) and the expression of CD14 and FCGR3A (right). e Heatmap showing the scaled signature scores of the KEGG signaling pathways across monocyte subpopulations. The signature scores were calculated via the “AddModuleScore” function in Seurat. f Boxplot showing the dynamics of the five monocyte subpopulations. Cell proportions were calculated as the percentage of total monocytes. g Boxplot showing the fold change in cell proportions of c36_Mono_LGALS2 and c38_mono_MX1 at different MSC treatment time points compared with baseline across the three cohorts of DLC patients. h Boxplot showing the dynamics of the CCR+ cMono proportion in CyTOF. i Violin plot showing the signature score of the cytokine production process in c38_mono_MX1. Related genes were derived from the Gene Ontology database. j Heatmap of bulk RNA-seq data showing the expression of MX1+ monocyte-specific genes before and after coculture with MSCs. The Wilcoxon rank-sum test was used to test the difference in cell proportion between groups (p-values highlighted in red) and between posttreatment and baseline in each cohort (p-values highlighted in the corresponding cohort color). ***p < 0.001. **p < 0.01. *p < 0.05CC BY · PubMed Central
Fig. 4 The variation in other immune cells and their interactions with monocytes in DLC patients under MSC treatment. a UMAP plot of the annotated T-cell subpopulations (left) and boxplots showing the dynamics of the major T-cell subpopulations (right). Cell proportions were calculated as the percentage of total T cells. Subpopulations with a maximum median proportion across groups over 5% are displayed. b t-SNE plot of the annotated T-cell subpopulations in CyTOF (left) and boxplot showing the dynamics of the three T-cell subpopulations in CyTOF (right). c Heatmaps showing the strength of ligand‒receptor pairs between c38_Mono_MX1 and four other immune cell subpopulations in four groups: healthy, baseline, D3, and D7. d Pie chart illustrating the correlations among cell subpopulations and indicating the differences between DLC patients at baseline and healthy individuals. The corresponding Spearman correlation coefficients are shown in the top-right corner. e Scheme showing the optimal efficacy timing of MSC treatment, its impact on immune cell subpopulations, and the key regulatory role of MX1+ monocytes. The Wilcoxon rank-sum test was used to test the difference in cell proportion between groups (p-values highlighted in red) and between posttreatment and baseline in each cohort (p-values highlighted in the corresponding cohort color). ***p < 0.001. **p < 0.01. *p < 0.05
Fig. 4 The variation in other immune cells and their interactions with monocytes in DLC patients under MSC treatment. a UMAP plot of the annotated T-cell subpopulations (left) and boxplots showing the dynamics of the major T-cell subpopulations (right). Cell proportions were calculated as the percentage of total T cells. Subpopulations with a maximum median proportion across groups over 5% are displayed. b t-SNE plot of the annotated T-cell subpopulations in CyTOF (left) and boxplot showing the dynamics of the three T-cell subpopulations in CyTOF (right). c Heatmaps showing the strength of ligand‒receptor pairs between c38_Mono_MX1 and four other immune cell subpopulations in four groups: healthy, baseline, D3, and D7. d Pie chart illustrating the correlations among cell subpopulations and indicating the differences between DLC patients at baseline and healthy individuals. The corresponding Spearman correlation coefficients are shown in the top-right corner. e Scheme showing the optimal efficacy timing of MSC treatment, its impact on immune cell subpopulations, and the key regulatory role of MX1+ monocytes. The Wilcoxon rank-sum test was used to test the difference in cell proportion between groups (p-values highlighted in red) and between posttreatment and baseline in each cohort (p-values highlighted in the corresponding cohort color). ***p < 0.001. **p < 0.01. *p < 0.05CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 1

  1. Feio-Azevedo, R. et al. Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure. Hepatology 81, 509–522 (2024). · DOI

Cited by

See all 21

Metadata

Authors
Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., Liu, K., Meng, F., Sun, J., Liu, W., Xie, X., Dong, T., Huang, L., Meng, F., Fu, J.-L., Li, Y., Zhang, C., Fan, X., Shi, M., Zhang, Y., Li, Y., Xie, W.-F., Zhang, P., & Wang, F.-S.
Affiliations
  • Chinese PLA General Hospital (CN)
  • Shanghai Jiao Tong University (CN)
  • Hubei University of Technology (CN)
  • Second Military Medical University (CN)
  • Capital Medical University (CN)
Corresponding author
  • Shi, Lei
  • Zhang, Peng
  • Wang, Fu-Sheng
Venue
Signal Transduction and Targeted Therapy
Published
2025-07-29
Volume
10
Issue
1
Pages
238-238
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4412726720
Cited by
16
References
58
Citations by year
2026: 12 · 2025: 4
FWCI
10.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Children's Research Centre
  • Sun Yat-sen University
  • Sichuan University
  • General Hospital of People’s Liberation Army
  • NIH Clinical Center
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
mesenchymal stem cells, cell therapy, decompensated cirrhosis, dose escalation, immunomodulation, monocyte subsets, safety and tolerability, multiple-dose regimen, Child-Pugh score, MELD score, liver function, single-cell RNA sequencing, multi-omics, liver fibrosis
MeSH terms
Adult, Aged, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Mesenchymal Stem Cell Transplantation, Immunomodulation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights. https://app.cochat.ai/papers/10.1038/s41392-025-02318-4
The paper
Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., Liu, K., Meng, F., Sun, J., Liu, W., Xie, X., Dong, T., Huang, L., Meng, F., Fu, J.-L., . . . Wang, F.-S. (2025). Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02318-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.